Problem

Obesity is a complex, chronic, and genetically influenced disease that poses a growing global health and economic burden.

Up to 80% of a person’s BMI is genetically determined, and the body actively resists weight loss through biological mechanisms—functioning much like a thermostat. Obesity must therefore be addressed as the chronic disease it truly is, rather than as a matter of lifestyle alone.

Yet, despite the severity of the issue, treatment coverage remains alarmingly low. Fewer than 0.5% of patients who could benefit from medical intervention are currently receiving it. This is largely due to existing therapies being costly, poorly accessible, and impractical for long-term adherence.

Current leading treatments—GLP-1 analogs—are injection-based, require ongoing administration, and are associated with side effects such as nausea and gastrointestinal discomfort. Adherence is low, and many patients experience weight regain after discontinuation. Long-term success often depends on combination therapy, which adds further complexity and cost.

There is a pressing unmet need for safe, effective, and user-friendly alternatives that can be scaled to reach the vast population living with obesity but currently left untreated. A sustainable solution must not only deliver results but also integrate seamlessly into patients’ daily lives.

Contact us for more information.